Added to YB: 2025-02-06
Pitch date: 2025-02-04
INMB [bearish]
INmune Bio, Inc.
+78.41%
current return
Author Info
Biotenic is a freelance L/S biotech investment analyst sharing investment theses. Sign up for the newsletter.
Company Info
INmune Bio, Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States.
Market Cap
$50.5M
Pitch Price
$9.31
Price Target
1.00 (-50%)
Dividend
N/A
EV/EBITDA
-0.44
P/E
-0.76
EV/Sales
351.78
Sector
Biotechnology
Category
special_situation
INMB (short) Ph2 alz data Q2
INMB: Alzheimer's Ph2 readout in Q2. Cash burn $10m/qtr, $30m on hand. Downside <$1 on failure. Primary endpoint EMACC not widely used. Ph1 data messy, selective disclosure. Skepticism due to data obfuscation, imbalanced baselines. Short thesis: financing need, red flags, high bar for success (CDR-SB).
Read full article (3 min)